LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.

The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.

The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.